Rituximab treatment seen to lower relapse risk in AAV patients in trial
People with relapsing ANCA-associated vasculitis (AAV) who achieved remission with rituximab and glucocorticoids have less than half the risk of experiencing a new relapse if they continue on rituximab treatment than if they start daily oral azathioprine. That’s according to the full results of the Phase 3…